

UCLA

UCLA Previously Published Works

Title

Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing

Permalink

<https://escholarship.org/uc/item/99k9d3xh>

Journal

Scientific Reports, 9(1)

ISSN

2045-2322

Authors

Yin, Yuxin

Reed, Elaine F

Zhang, Qiheng

Publication Date

2019

DOI

10.1038/s41598-019-44336-7

Peer reviewed

SCIENTIFIC REPORTS

OPEN

Integrate CRISPR/Cas9 for protein expression of *HLA-B*38:68Q* via precise gene editing

Yuxin Yin, Elaine F. Reed & Qiheng Zhang 

The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem cell transplantation and solid organ transplantation. We studied the expression level of a questionable (Q) *HLA-B*38:68Q* allele, which carries a 9-nucleotide (nt) deletion at codon 230–232 in exon 4 of *HLA-B*38:01:01:01* using CRISPR/Cas9 gene editing technology. CRISPR/Cas9 gene editing of *HLA-B*38:01:01:01* homozygous EBV B cell line resulted in one *HLA-B*38:68Q/B*38:01:01:01* heterozygous and one *HLA-B*38:68Q* homozygous clone. Flow cytometric analysis of monoclonal anti-Bw4 antibody showed the protein expression of *HLA-B*38:01:01:01* in homozygous cells was 2.2 fold higher than *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells, and the expression of *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells was over 2.0 fold higher than *HLA-B*38:68Q* homozygous cells. The *HLA-B*38:68Q* expression was further confirmed using anti-B38 polyclonal antibody. Similarly, the expression of the *HLA-B*38:01:01:01* homozygous cells was 1.5 fold higher than that of *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells, and the *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells was over 1.6 fold higher than that of *HLA-B*38:68Q* homozygous cells. The treatment of *HLA-B*38:68Q* homozygous cells with IFN- γ significantly increased its expression. In conclusion, we demonstrate that *HLA-B*38:68Q* is a low-expressing HLA allele. The CRISPR/Cas9 technology is a useful tool to induce precise gene editing in HLA genes to enable the characterization of HLA gene variants on expression and function.

Immune recognition of infectious pathogens is mediated through the presentation of foreign peptides by the Human Leukocyte Antigen (HLA) molecules¹. The HLA class I (HLA-A, -B and -C) and class II (HLA-DR, -DQ and -DP) are the most polymorphic genes in the human genome with 18,771 different HLA alleles identified (IMGT/HLA v3.33.0)². The high level of HLA polymorphism reflects its biological importance to present a large diversity of peptides to the immune system and trigger effective immune responses³. In allogeneic hematopoietic stem cell transplantation (HSCT), HLA mismatches between donor and recipient leads to strong alloimmune responses that result in either graft versus host disease (GVHD) or engraftment failure^{4–6}.

Mutations such as insertions, deletions in HLA sequences can lead to the introduction of stop codons and/or incorrectly spliced products that result in aberrant expressed alleles. HLA null alleles (N) are characterized by the lack of antigen expression of the HLA molecule on cell surface². Failure to identify HLA null alleles in donors may result in HLA mismatches that can stimulate allogeneic T cells and trigger GVHD in HSCT⁷. A 'Q' suffix is used for HLA alleles that their expressions have not been confirmed and remain 'Questionable'. In HSCT, if the presence of a questionable allele in the donor is in fact a null allele, mistyping the null allele results in an antigen mismatch between the donor and the recipient and increases the risk of GVHD⁷. On the contrary, mistyping of a lowly expressed HLA allele as a null allele in the recipient can lead to inaccurate donor selection and result in GVHD as well. Therefore, questionable alleles require confirmation of their actual HLA expression level. For example, *HLA-A*23:19Q* has a single polymorphism at position 619 (G > A) compared to *HLA-A*23:01:01*. Gerritsen *et al.* demonstrated that *HLA-A*23:19Q* has no expression by serology and flow cytometry, therefore it should be reclassified as a null allele⁸. Hirv *et al.*⁹ reported a patient, who carried *HLA-A*30:14L* and *HLA-A*02:01* alleles, was mistyped as *HLA-A*02:01* homozygous. The mistyping of *HLA-A*30:14L* led to severe GVHD in the patient transplanted with HSCT from an *HLA-A*02:01* homozygous donor. Currently, there are 663 null alleles (N), 44 questionable alleles (Q), 5 low expression alleles (L), and 1 soluble alleles (S) identified in IMGT/HLA data base². The HLA matching of the questionable alleles between the donor and recipient

UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine, Los Angeles, 90095, USA. Correspondence and requests for materials should be addressed to Q.Z. (email: jqzhang@mednet.ucla.edu)




Figure 1. crRNA and ssDNA target design. **(A)** Comparison of *HLA-B*38:01:01:01* and *HLA-B*38:68Q* in nucleotide and protein sequences. Yellow box highlights the 9-nt deletion mutation and “” indicates the deletion. Numbers above sequence correspond to amino acid codon positions. **(B)** HLA typing of TEM665 homozygous *HLA-B*38:01:01:01* EBV transformed B cell line used for gene editing. **(C)** Design of crRNA and ssDNA target on *HLA-B*38:01:01:01*. crRNA1 and crRNA2 are colored in green. The Protospacer Adjacent Motif (PAM) recognition sites are marked in blue. The red box indicates the location of 9-nt deletion. “” means that the ssDNA oligo contains the 9-nt deletion. Blue arrows show the position of double strand breaks (DSBs) that should be introduced by CRISPR/Cas9.

remains challenging. Therefore, it is important to determine the expression patterns of abnormally expressed HLA variants⁷.

The CRISPR (clustered regularly interspaced short palindromic repeats) is an adoptive immune system in bacteria that protects the bacterium from invading foreign genetic elements such as plasmid and bacteriophages¹⁰. The CRISPR/Cas9 system contains two components: a guide RNA (gRNA) and a CRISPR-associated endonuclease (Cas protein)^{11,12}. The gRNA is a short RNA composed of a scaffold sequence needed for Cas-binding and a user-defined ~20 nucleotide spacer that defines the genomic target to be modified¹³. The gRNA spacer sequence could be designed to target DNA sites with Protospacer Adjacent Motif (PAM)^{14,15}. The most common PAM sequence recognized by Cas9 is NGG that is found directly downstream of the target DNA. The CRISPR/Cas9 cuts double strand DNA to generate double strand breaks (DSBs) between 3–4 bp upstream of the NGG PAM under the guidance of gRNA¹⁶. The DSBs can be repaired by non-homologous end joining (NHEJ), which is an error-prone process that introduces unpredictable insertions and deletions (indels); DSBs can also be repaired by homology directed repair (HDR) with the presence of DNA template, which induces desired DNA editing^{11,12,17}. Two types of the DNA template can be used for HDR: a small single stranded DNA (ssDNA) oligonucleotide with 30–67 nt homology arms flanking the gene editing site¹⁸ or a double stranded DNA (dsDNA) plasmid with long homology arms of 1–3 kb¹⁹.

The recent discovery of CRISPR/Cas9 system provides a faster and more economical approach to gene editing²⁰ compared to the traditional zinc-finger nucleases (ZFNs)²¹ and transcription activator-like effector nuclease (TALEN) methods²². The goal of this study was to generate homozygous and heterozygous cells carrying the *HLA-B*38:68Q* with deletion at codon 230–232 at exon 4 using CRISPR/Cas9 gene editing to study the effect of this mutation on *HLA-B*38:01:01:01* expression.

Results

crRNA design and selection. We identified a new HLA B allele that is similar to *HLA-B*38:01:01:01* except for a nine-nucleotide deletion (5'-CTTGTGGAG-3') at codon 230 to 232 that results in a coding shift at $\alpha 3$ domain of *HLA-B38* (Fig. 1A). The sequence was submitted to the GenBank database (accession number MF069211) and IMGT/HLA databases (submission number HWS10028807). Since the expression level of this novel B*38 allele is unknown, it was named *HLA-B*38:68Q*. To determine if the deletion at codon 230–232 affected the level of protein expression, the homozygous *HLA-B*38:01:01:01* EBV B cell line TEM665 was used to generate homozygous *HLA-B*38:68Q* alleles to study its expression (Fig. 1B). GeneArt™ CRISPR Search and Design Tool was used to design crRNAs targeting the DNA sequences close to the 9-nt deletion site at exon 4 of



Figure 2. Single cell clones derived by CRISPR/Cas9-mediated gene editing. Nucleotides highlighted in red are the position with the 9-nt deletion. The Protospacer Adjacent Motif (PAM) sequence is highlighted in green. “.” indicates the deletion. The frequency of each single cell derived clone as well as the relative percentage of wild type (WT), NHEJ, and HDR were listed (n = 25).

*HLA-B*38:01:01:01* (Fig. 1C). crRNA1 (5'-GGATGGCGAGGACCAAACCTC-3') was designed to recognize -12 to -31 bp upstream of the 9-nt deletion, and crRNA2 (5'-TGGTCTGGTCTCCACAAGCT-3') was designed to recognize -2 to +9 bp sequence of the 9-nt deletion. Both crRNAs share a ssDNA target with a 67-nt of left arm and a 30-nt of right arm of the deletion site (Fig. 1C). The crRNA1 and crRNA2 were then mixed with universal tracrRNA to form gRNA1 and gRNA2. Next, Cas9 protein (1.5 µg) and gRNA1/gRNA2 (360 ng) were mixed to form Cas9 ribonucleoprotein (RNP), respectively¹⁸. Twenty four electroporation conditions were tested to optimize transposition efficiency using Neon transfection system²³ (Supplemental Table 1). The program of the highest transposition efficiency (58.4%) was selected for transfecting *HLA-B*38:01:01:01* homozygous EBV B cell line. Our results showed that gRNA1 induced 22.6% DSB cleavage and gRNA2 induced 13.8% DSB cleavage using GeneArt® Genomic Cleavage Detection assay. The gRNA1 was chosen for transfection with ssDNA target due to its high efficiency.

Generation of *HLA-B*38:68Q* clones using CRISPR/Cas9 gene editing. Gene editing of *HLA-B*38:01:01:01* homozygous EBV B cell line by CRISPR/Cas9 using gRNA1 resulted in 25 single cell derived clones. The 25 clones were then sequenced by Next Generation Sequencing (NGS) to ensure correct gene editing was achieved (Fig. 2). The CRISPR/Cas9 editing is usually bi-allelic. Our results showed a total of 41 alleles were edited while 9 alleles had no editing. These 41 edited alleles resulted in 21 (84%) modified clones with 7 genotypes (Fig. 2). Of the 25 clones, 5 alleles (10%) were edited through the HDR pathway and 36 alleles (72%) were edited through the NHEJ pathway. The most frequent editing was an A deletion at codon 225 through NHEJ pathway which resulted in 11 (44%) clones with homozygous A deletion (Clone 7, Fig. 2). The CRISPR/Cas9 editing generated 5 *HLA-B*38:68Q* alleles that resulted in one *HLA-B*38:68Q* homozygous clone and one *HLA-B*38:01:01:01/B*38:68Q* heterozygous clone. The sequencing of the entire HLA-B gene from the 5' UTR to 3' UTR of the *HLA-B*38:68Q* homozygous clone and a *HLA-B*38:01:01:01/B*38:68Q* heterozygous clone showed that other than the correct 9-nt deletion on codon 230–232 at exon 4, there was no non-specific gene editing detected in the rest of the *HLA-B*38:68Q* alleles in both clones (Fig. 3).

***HLA-B*38:68Q* shows inferior cell surface expression by flow cytometry.** Both *HLA-B*38:68Q* and *HLA-B*38:01:01:01* express Bw4 epitope in α 1-helix at position 77–83²⁴, therefore anti-Bw4 antibody was used to detect the expression levels of *HLA-B*38:68Q* homozygous and *HLA-B*38:68Q/B*38:01:01:01* heterozygous clones. The monoclonal anti-Bw4 antibody does not cross reactive to A66, C12 HLA antigens expressed on the *HLA-B*38:01:01:01* homozygous TEM665 EBV B cell line using Luminex Single Antigen Bead (SAB) testing (Supplemental Fig. 1). The K562 cell line lacking HLA molecule expression and the Bw6 homozygous AOH749 EBV B cell line were used as negative controls. The wild type *HLA-B*38:01:01:01* homozygous TEM665 EBV B cell line was used as a positive control (Fig. 1B). Flow cytometry analysis showed the median fluorescence intensity (MFI) of antibody binding to *HLA-B*38:01:01:01* was at 58,080 ± 5,368 MFI in the *HLA-B*38:01:01:01* homozygous TEM665 EBV B cell line compared to 10,383 ± 639 MFI in homozygous *HLA-B*38:68Q* cells using 2 µL of anti-Bw4 antibody (Fig. 4). As expected, HLA expression was negative in AOH749 and K562 cell line (Fig. 4). These results indicate that *HLA-B*38:68Q* is expressed on the cell surface, yet at a significantly lower level than the wild type *HLA-B*38:01:01:01* molecule. Notably, the expression of *HLA-B*38:01:01:01* homozygous cell line was 2.2 fold higher than *HLA-B*38:68Q/B*38:01:01:01* heterozygous clones (24,067 ± 2,066 MFI, $P < 0.01$). In addition, the expression of *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells was 2.0 fold higher than *HLA-B*38:68Q* homozygous clone ($P < 0.001$), suggesting *HLA-B*38:68Q* exhibits a reduction of antigen expression in a gene dose dependent manner (Fig. 4). Similar results were found using 0.5 µL and 1 µL of anti-Bw4 antibody (Fig. 4).




Figure 3. Confirmation of *HLA-B*38:68Q* gene editing by NGS sequencing. (A) *HLA-B*38:01:01:01* homozygous; (B) *HLA-B*38:68Q/B*38:01:01:01* heterozygous; (C) *HLA-B*38:68Q* homozygous. The histograms display NGS read coverage from 5' UTR to 3' UTR. The purple color represents exons. The height of the blue (specific reads from one allele), green (homozygous sequences), and grey (sequences shared by both alleles) colors indicates relative read depth. The highest and lowest coverages are shown with numbers. Sequence in red indicates the location of 9-nt, and " " indicates the 9-nt deletion.




Figure 4. Flow cytometric analysis of *HLA-B38* protein expression using monoclonal antibody. (A) *HLA-B* expression detected in *HLA-B*38:01:01:01* homozygous (blue), *HLA-B*38:68Q/B*38:01:01:01* heterozygous (red), *HLA-B*38:68Q* homozygous (green), and negative controls (AOH749 purple and K562 in orange) using anti-Bw4 IgG antibody. Samples were tested in triplicate and the expression level is shown as mean fluorescence intensity (MFI) \pm SD. (B) Representative histograms of *HLA-B* expression in *HLA-B*38:01:01:01* homozygous, *HLA-B*38:68Q/B*38:01:01:01* heterozygous, *HLA-B*38:68Q* homozygous and negative controls using 0.5 μ L of anti-Bw4 IgG antibody. Normalized to mode scales all channels as a percentage of the maximum count. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, and NS indicates the variables are not significant.




Figure 5. Flow cytometric analysis of *HLA-B38* expression using polyclonal antibody. *HLA-B38* expression is shown in *HLA-B*38:01:01:01* homozygous (blue), *HLA-B*38:68Q/B*38:01:01:01* heterozygous (red), *HLA-B*38:68Q* homozygous (green) and K562 negative control (purple) using anti-B38 antibody from UCLA serum exchange. Samples were tested in triplicate and the expression level is shown as mean fluorescence intensity (MFI) \pm SD. *** $P < 0.001$, **** $P < 0.0001$, and NS indicates the variables are not significant.

The expression of the *HLA-B*38:68Q* was further confirmed using human polyclonal antibody against *HLA-B38* at neat and at 1:2 dilution. *HLA-B38* antibody recognizes epitopes at 80I and 158 T of the $\alpha 1$ and $\alpha 2$ helixes of HLA class I molecule²⁵. The polyclonal anti-B38 antibody does not cross react to A66, C12, DR14, DR52, DQ5 and DP1 HLA antigens expressed on the *HLA-B*38:01:01:01* homozygous TEM665 EBV B cell line using Luminex SAB test (Supplemental Fig. 2). Luminex SAB testing showed the MFI of the *HLA-B38* antibody was 22,636 at neat and 14,551 at 1:2 dilution. Our results showed the expression of *HLA-B38* in the *HLA-B*38:01:01:01* homozygous cells ($27,730 \pm 784$ MFI) was 1.5 fold higher than that of *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells ($18,184 \pm 387$ MFI, $P < 0.0001$), and the *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells was over 1.6 fold higher than *HLA-B*38:68Q* homozygous cells at neat ($11,427 \pm 190$ MFI, $P < 0.0001$, Fig. 5). Similar results were found using anti-B38 antibody at 1:2 dilution. In summary, this data demonstrates that *HLA-B*38:68Q* is a low-expressed HLA allele, not a null allele.

Allograft rejection often correlates with increased cytokine production including IFN- γ ²⁶. We therefore tested if the expression of *HLA-B*38:68Q* will be stimulated by IFN- γ under inflammatory environment. Our results showed that in the *HLA-B*38:68Q* homozygous cells, the treatment of IFN- γ significantly increased the HLA-B expression and resulted in a binding of $36,036 \pm 887$ MFI, 1.9 fold higher than the *HLA-B*38:68Q* homozygous cells without IFN- γ treatment ($19,379 \pm 900$ MFI, $P < 0.0001$, Fig. 6). Similarly, in the *HLA-B*38:01:01:01* homozygous cells, the expression of HLA-B treated with IFN- γ was at $57,646 \pm 357$ MFI, which was 1.2 fold higher than the untreated group ($46,642 \pm 231$ MFI, $P < 0.0001$). The results showed that although the expression of *HLA-B*38:68Q* can be upregulated by IFN- γ treatment, the upregulation of HLA-B expression was much lower compared to IFN- γ treated *HLA-B*38:01:01:01* homozygous cells (Fig. 6).

Discussion

In this study, we reported efficient *HLA-B*38:01:01:01* gene modification and expression in an EBV B cell line using the CRISPR/Cas9 system. We successfully introduced gene editing in 84% of clones and achieved precise deletion at codon 230–232 at exon 4 in 5 alleles. Similar to other publications, the CRISPR/Cas9 gene editing of *HLA-B*38:01:01:01* involved DNA repair via either NHEJ or HDR pathway²⁷. However, even in the presence of guided DNA templates, 72% of gene editing was through the NHEJ repair pathway compared to 10% in HDR pathway. HDR pathway provides desired repair of the target DNA in the presence of template DNA. The low incidence of HDR makes the selection of precise gene editing challenging. In order to achieve higher HDR gene editing efficiency, the DSBs induced by CRISPR/Cas9 nuclease should be in close proximity to the edit site¹⁸. The homologous recombination rate could be increased with larger flanking sequences, therefore standard gene deletion/disruption protocols typically use flanking regions over 1 kb on either side of the target gene to increase HDR²⁸. The evidence of using cell lines deficient in NHEJ pathways increased the levels of HDR suggesting these two pathways are competitive²⁹. Recent studies have demonstrated the use of KU70, KU80 or DNA ligase IV to suppress key NHEJ molecule can increase HDR pathway³⁰.

Our study successfully demonstrated that the deletion at codon 230–232 at exon 4 in *HLA-B*38:01:01:01* reduced *HLA-B38* antigen expression on the cell surface using CRISPR/Cas9 system. The expression of the *HLA-B*38:01:01:01* homozygous allele was 2.2 fold higher than *HLA-B*38:68Q/B*38:01:01:01* heterozygous cells. Further, *HLA-B*38:68Q/B*38:01:01:01* protein expression in heterozygous cells was >2.0 fold higher compared to *HLA-B*38:68Q* homozygous cells. Similar results were found using the anti-B38 polyclonal antibody. These




Figure 6. IFN- γ induced *HLA-B38* cell surface expression. *HLA-B* expression of *HLA-B*38:01:01:01* homozygous cell line (untreated in purple and IFN- γ treated in orange) and *HLA-B*38:68Q* homozygous cell line (untreated in blue and IFN- γ treated in red) was determined using anti-Bw4 IgG antibody. Samples were tested in triplicate and the expression level is shown as mean fluorescence intensity (MFI) \pm SD. **** P < 0.0001, and NS indicates the variables are not significant.

results suggested that the deletion of three amino acids (LVE) at exon 4 of *HLA-B*38:01:01:01* reduces the protein expression level. In addition, our data also showed that after IFN- γ treatment, the expression of *HLA-B*38:68Q* was significantly increased compared to the untreated cells. These results suggested that *HLA-B*38:68Q* may still play an important role in allograft rejection³¹. However, the expression increase of the *HLA-B*38:68Q* with the IFN- γ treatment was much lower compared to the *HLA-B*38:01:01:01* homozygous cells. The cause of the reduced expression of *HLA-B*38:68Q* allele is unclear and requires additional study. However, possible mechanisms that proposed for lower HLA expression including aberrant dominate splice site, such as *A*24:02:03Q*³² and HLA conformation alterations caused by disulfide bond changes, such as *A*32:11Q*³³.

Currently, there are 44 questionable HLA alleles (Q) in IMGT/HLA data base². The frequency of these questionable alleles has not been well established, particularly the HLA allele frequency is largely based on the Caucasian population. Therefore, the frequency of these questionable alleles may be underestimated in other populations. With the advancement of the full gene HLA sequencing by NGS technology, the laboratory is able to obtain high resolution HLA typing with minimum ambiguities. However, due to additional sequencing information on exons outside the antigen recognition sites (ARS) and introns, it is likely that more questionable alleles will be discovered. The knowledge of the expression level of these questionable alleles may be important for donor selection in HSCT. Petersdorf *et al.* demonstrated that increasing expression level of the patient's mismatched HLA-C allele was associated with increased risk of grades III-IV acute GVHD with odds ratio of 1.34 in HSCT³⁴. In addition, the understanding of the expression level can also help to identify donors with the least immunogenic mismatches, or select donors to cross permissive immunological barriers for highly sensitized patients in solid organ transplantation. These questionable alleles could also be potential null alleles. Failure to identify HLA null alleles in donors may cause severe GVHD in HSCT⁷. Increasing knowledge of the expression level of HLA variant alleles will help to improve the understanding of HLA allogenicity in both HSCT and solid organ transplantation. The CRISPR/Cas9 system provides an effective tool to study the expression level of these variant HLA alleles. In addition, CRISPR/Cas9 can also introduce insertions and deletions at the UTRs, exons and introns to study the regulations and functions of HLA genes.

CRISPR/Cas9 has been used to facilitate correction of mutated genes in various diseases. Recently, CRISPR/Cas9 has been used to treat single nucleotide polymorphism in the β -globulin gene to treat sickle cell diseases in a mouse model³⁵. The chimeric antigen receptor (CAR) modified T cells have been applied to various cancers, especially in B cell hematologic malignancies³⁶. With the application CRISPR/Cas9 system, Liu *et al.*³⁷ have successfully down regulated the expression of HLA class I and TCR α to generate a universal chimeric antigen receptor (CAR) T cells. The CRISPR/Cas9 technology has also come under the spotlight in transplantation. Entry of human immunodeficiency virus (HIV) into target cells requires both CD4 and CCR5 receptors³⁸. A 32-base pair deletion in CCR5 (CCR5- Δ 32) is associated with reduced HIV transmission risk and delayed disease progression³⁹. In HIV+ patients with hematological malignancies, gene editing using CRISPR/Cas9⁴⁰ has been used to generate homozygous CCR5- Δ 32 deletion in CD34+ cells to introduce HIV resistance. Currently, there are several ongoing clinical trials evaluating the safety of transplantation of CRISPR modified CCR5- Δ 32 CD34+ cells in HIV+ patients with hematological malignancies^{41,42}. In conclusion, the CRISPR/Cas9 system is a powerful gene editing tool that can be used to study HLA gene expression and function and improve HLA matching in hematopoietic stem cell and solid organ transplantation. Modification of HLA gene expression by CRISPR/Cas9 also promises to provide new approaches for cellular therapies in transplantation.

Material and Methods

*HLA-B*38:68Q* was submitted to the GenBank database (accession number MF069211) and IMGT/HLA database (submission number HWS10028807) with full genomic allele sequence as a questionable allele due to its unknown surface expression by our center in 2017⁴³. Research approval for performing CRISPR/CAS9 on the sample was granted by the UCLA Institutional Review Board (IRB#14-000516).

Cell lines. An *HLA-B*38:01:01:01* homozygous EBV transformed B cell line TEM665 (from International Histocompatibility Workshop, IHW9057, Fig. 1B) was selected for gene editing, and in addition, a Bw6 homozygous EBV B cell line AOH749 (from AOH Workshop, AOH9004) and/or K562 (from UCLA Immunogenetics Center) which lacks HLA expression were used as negative controls for monoclonal or polyclonal antibody test. AOH749 expresses HLA A31, B65, Bw6, C8, DR1, DQ5, DP3 and DP0401, which does not cross reactive to the anti-Bw4 antibody. All cell lines were cultured in RPMI-1640 (GE Healthcare Life Sciences, USA) containing 20% FBS (Omega, USA), 1% Amphotericin B (Corning, USA), 1% Penicillin Streptomycin Solution (Corning, USA), 1% Gibco™ Sodium Pyruvate (100mM) (ThermoFisher, USA), 1% Gibco™ MEM Non-Essential Amino Acids Solution (ThermoFisher, USA), and 0.1% Gibco™ 2-Mercaptoethanol (55 mM) (ThermoFisher, USA). All cultures were maintained in 5% CO₂, 37°C.

crRNA design and Cas9 Ribonucleoproteins (RNPs) complex formation. Oligonucleotides of crRNA sequences were designed with the GeneArt™ CRISPR Search and Design Tool. crRNAs (Synthesized by ThermoFisher, USA) and tracrRNA from TrueGuide™ Synthetic gRNA kit (ThermoFisher, USA) were re-suspended using DNA Suspension Buffer pH 8.0 (Teknova, USA) to make a concentration of 100 pM. In Brief, the reaction of forming gRNA consisted of 10 μL crRNA, 10 μL tracrRNA, 10 μL annealing buffer, and 20 μL nuclease-free H₂O, making a final volume of 50 μL. Then the mixture was incubated at 95 °C for 5 mins followed by 10 mins on 78 °C, and then 25 °C for 5 mins. To make Cas9 RNPs, mixing the following items: 11.25 μL gRNA formed in previous step, 7.5 μL Cas9 Nuclease V2 (5 μg/μL) (ThermoFisher, USA), and 131.25 μL buffer R from Neon kit (Invitrogen, USA), making a final volume of 150 μL. The mixture was incubated at room temperature for 10–20 mins.

ssDNA target design/Homologous recombination assays. To create homologous recombination (HR) assays, two gRNAs target the sequence near the deletion site within the HLA-B gene were designed and synthesized¹⁸. The Cas9 RNPs were then used to transfect cells via Neon® electroporation (Invitrogen, USA) for 24-well format electroporation transfection testing for B cell line. The genomic cleavage efficiency was then evaluated using the GeneArt® Genomic Cleavage Detection kit (ThermoFisher, USA) at 48 h post transfection. The cleavage efficiencies were calculated based on the relative agarose gel band intensity, which was quantified using a high sensitivity DNA chip on TapeStation 2200 (Agilent, USA). Cleaved efficiency was calculated following the manufacturer's instruction. A program with voltage set at 1700 V, pulse width set at 20 ms, and one pulse was used for the subsequent study. The gRNA with highest editing was selected for the subsequent HR assays. For ssDNA target design, typically the mutation site was positioned at the center flanked by 67-nt to 30-nt on each side (Fig. 1C). To measure homologous recombination efficiency, the ssDNA target was co-transfected with Cas9 RNPs into cells via electroporation. The genomic loci were PCR-amplified using the corresponding primers and then subjected to GeneArt® Genomic Cleavage Detection assay (ThermoFisher, USA) for restriction enzyme digestion.

Culture of single cell derived clones. Transfected cells were washed with 500 μL of PBS buffer (Corning, USA) and resuspended at the density of 8 cells/mL with a total volume of 50 mL. 100 μL of the cell suspension was transferred into the wells of the 96 well tissue culture plates to ensure each well contained a single cell. The plates were incubated at 37 °C, 5% CO₂ incubator (Thermo Scientific, USA). The plates were then scanned for single cell colonies as soon as small aggregates of cells are visible under a 4× microscope (usually after first week, depending on the growth rate of the cell line) to ensure the cell colonies were derived from a single cell. The cells were incubated for an additional 2–3 weeks to expand the clonal populations for further analysis and characterization.

Harvest single cell derived clones. Single cell derived clones were washed with 100 μL of 1× PBS buffer (Corning, USA). 1 × 10⁵ of the cells from each clones were transferred into the PCR plate containing 25 μL “Direct lysis buffer”. The “Direct lysis buffer” was made by adding 10 μL of Proteinase K (Thermo Scientific, USA) to 1 mL DirectPCR Lysis Reagent (Thermo Scientific, USA). The PCR plate was incubated at 55 °C for 30 mins to lyse the cells and followed by 95 °C for 45 mins to denature the Proteinase K.

HLA gene amplification and next generation sequencing. Multiplex long-range PCR were employed using AllType NGS assay (One Lambda, USA) to co-amplify 11 HLA loci including HLA-A, -B, -C, -DRB1,3,4,5 -DQB1 -DPB1, -DQA1 and -DPA1. HLA-A, -B, -C, -DQA1, and -DPA1 were amplified from 5'UTR to 3'UTR, and remaining loci are beginning at intron 1 to 3'UTR. Library construction was automated on the Biomek FX (Beckman coulter, USA). Sequence-ready libraries were validated and quantitated on the High Sensitivity D1000 ScreenTape (Agilent Technologies, USA) to allow for library normalization and equimolar pooling of all study samples on the Biomek FX (Beckman coulter, USA). Pooled libraries were diluted and loaded at Ion Chef (Thermo Scientific, USA) for template amplification. Sequencing on Ion S5 XL is followed the manufacture instruction (Thermo Scientific, USA). When the sequencing was done, the TSVEngine v1.2.0 (One Lambda, USA) was employed to analyze the data.

Single antigen antibody testing. Neat and serum at 1:2 dilution were treated with DTT and tested for HLA antibodies using the IgG-SAB Assay from One Lambda (Canoga Park, CA) as previously described⁴⁴. Antibodies were considered positive if the MFI >1000 for HLA-A, -B, -DR, -DQ and >2000 was used for HLA-C and -DP to correct for the enhanced amount of HLA-C and -DP antigens conjugated to the Luminex beads compared to the lower cell surface expression on lymphocytes.

Flow cytometric analysis of HLA protein expression. Expression of HLA-B locus antigens in the edited cell lines containing the *HLA-B*38:68Q* allele and control cells were determined by flow cytometry using a FITC-conjugated monoclonal anti-IgG Bw4 antibody (One Lambda, USA). Approximately 10^5 cells were incubated with 0.5, 1, and 2 μ L (10 mg/mL) anti-Bw4 monoclonal antibody on ice for 30 mins. Isotype control cells were incubated with 0.5 μ L of FITC-conjugated mouse IgG secondary antibody (Jackson ImmunoResearch, USA). After staining, cells were washed with $1 \times$ PBS buffer (Corning, USA) containing 2% FBS (Omega, USA) and suspended in 300 μ L of PBS/2% FBS. TEM665 homozygous *HLA-B*38:01:01:01* EBV transformed B cell line was used as the positive control, AOH749 and K562 were used as the negative control cells. Samples were tested in triplicate. Analysis of HLA B locus expression was performed using FlowJo software version 10 (BD, USA).

Expression of *HLA-B38* in the edited cell lines containing the *HLA-B*38:68Q* allele was determined using UCLA serum exchange sample that contains anti-B38 antibody but lacks Bw4 activity. Approximately 1.5×10^5 cells/tube were incubated with 25 μ L UCLA serum exchange serum at neat and 1:2 dilution for 30 mins at room temperature. After incubation, cells were washed 4 times with PBS/2% FBS followed by labeling for 20 mins at 4 °C with an anti-human IgG FITC-conjugated antibody (Jackson ImmunoResearch, USA). Negative sera routinely used in the clinical lab were used as controls. Samples were tested in triplicate. Analysis of *HLA-B38* expression was performed using FlowJo software version 10 (BD, USA).

IFN- γ induced *HLA-B*38:68Q* cell surface expression. The *HLA-B*38:68Q* homozygous cell line and TEM665 *HLA-B*38:01:01:01* homozygous EBV transformed B cell line (served as positive control) were pre-treated with 500 U/mL of IFN- γ (R&D Systems, USA) for 48 h. The expression of HLA-B expression of the IFN- γ treated and untreated cell lines were determined using monoclonal anti-IgG Bw4 antibody (One Lambda, USA) by flow cytometry. A FITC-conjugated anti-mIgG (BioXCell, USA) was used as an isotype control. Samples were tested in triplicate. Analysis of expression was performed using FlowJo software version 10 (BD, USA).

Statistical analysis. Each experiment of protein expression was tested in triplicate and the expression level is shown as mean fluorescence intensity (MFI) \pm SD. Statistical analysis was performed the Student's *t* test or ANOVA on GraphPad Prism 7 (GraphPad, USA). *P* < 0.05 was denoted as significant.

Data Availability

All data generated or analyzed during this study are included in this article.

References

- Klein, J. & Sato, A. The HLA system. First of two parts. *N Engl J Med* **343**, 702–709, <https://doi.org/10.1056/NEJM200009073431006> (2000).
- Robinson, J. *et al.* The IMGT/HLA database. *Nucleic Acids Res* **41**, D1222–1227, <https://doi.org/10.1093/nar/gks949> (2013).
- Bodmer, W. F. The HLA system: structure and function. *J Clin Pathol* **40**, 948–958 (1987).
- Parham, P. & Ohta, T. Population biology of antigen presentation by MHC class I molecules. *Science* **272**, 67–74 (1996).
- Lee, S. J. *et al.* High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood* **110**, 4576–4583, <https://doi.org/10.1182/blood-2007-06-097386> (2007).
- Woolfrey, A. *et al.* HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* **17**, 885–892, <https://doi.org/10.1016/j.bbmt.2010.09.012> (2011).
- Elsner, H. A. & Blaszczak, R. Immunogenetics of HLA null alleles: implications for blood stem cell transplantation. *Tissue Antigens* **64**, 687–695, <https://doi.org/10.1111/j.1399-0039.2004.00322.x> (2004).
- Gerritsen, K. E. *et al.* RNA and protein expression of HLA-A(*)23:19Q. *Hum Immunol* **76**, 286–291, <https://doi.org/10.1016/j.humimm.2015.02.001> (2015).
- Hirv, K., Pannicke, U., Mytilineos, J. & Schwarz, K. Disulfide bridge disruption in the alpha2 domain of the HLA class I molecule leads to low expression of the corresponding antigen. *Hum Immunol* **67**, 589–596, <https://doi.org/10.1016/j.humimm.2006.04.010> (2006).
- Wiedenheft, B., Sternberg, S. H. & Doudna, J. A. RNA-guided genetic silencing systems in bacteria and archaea. *Nature* **482**, 331–338, <https://doi.org/10.1038/nature10886> (2012).
- Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science* **346**, 1258096, <https://doi.org/10.1126/science.1258096> (2014).
- Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. *Nat Rev Genet* **16**, 299–311, <https://doi.org/10.1038/nrg3899> (2015).
- O'Connell, M. R. *et al.* Programmable RNA recognition and cleavage by CRISPR/Cas9. *Nature* **516**, 263–266, <https://doi.org/10.1038/nature13769> (2014).
- Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821, <https://doi.org/10.1126/science.1225829> (2012).
- Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**, 2281–2308, <https://doi.org/10.1038/nprot.2013.143> (2013).
- Liang, X. *et al.* Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. *J Biotechnol* **208**, 44–53, <https://doi.org/10.1016/j.jbiotec.2015.04.024> (2015).
- Zhang, F., Wen, Y. & Guo, X. CRISPR/Cas9 for genome editing: progress, implications and challenges. *Hum Mol Genet* **23**, R40–46, <https://doi.org/10.1093/hmg/ddu125> (2014).
- Liang, X., Potter, J., Kumar, S., Ravinder, N. & Chesnut, J. D. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. *J Biotechnol* **241**, 136–146, <https://doi.org/10.1016/j.jbiotec.2016.11.011> (2017).
- Rong, Z., Zhu, S., Xu, Y. & Fu, X. Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. *Protein Cell* **5**, 258–260, <https://doi.org/10.1007/s13238-014-0032-5> (2014).
- Miyagi, A., Lu, A. & Humphreys, B. D. Gene Editing: Powerful New Tools for Nephrology Research and Therapy. *J Am Soc Nephrol* **27**, 2940–2947, <https://doi.org/10.1681/ASN.2016020146> (2016).
- Ochiai, H. & Yamamoto, T. Construction and Evaluation of Zinc Finger Nucleases. *Methods Mol Biol* **1630**, 1–24, https://doi.org/10.1007/978-1-4939-7128-2_1 (2017).
- Kim, Y. H. *et al.* Rh D blood group conversion using transcription activator-like effector nucleases. *Nat Commun* **6**, 7451, <https://doi.org/10.1038/ncomms8451> (2015).

23. Yu, X. *et al.* Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. *Biotechnol Lett* **38**, 919–929, <https://doi.org/10.1007/s10529-016-2064-9> (2016).
24. Lutz, C. T. Human leukocyte antigen Bw4 and Bw6 epitopes recognized by antibodies and natural killer cells. *Curr Opin Organ Transplant* **19**, 436–441, <https://doi.org/10.1097/MOT.000000000000103> (2014).
25. Duquesnoy, R. J. Reflections on HLA Epitope-Based Matching for Transplantation. *Front Immunol* **7**, 469, <https://doi.org/10.3389/fimmu.2016.00469> (2016).
26. Hidalgo, L. G. & Halloran, P. F. Role of IFN-gamma in allograft rejection. *Crit Rev Immunol* **22**, 317–349 (2002).
27. Nimonkar, A. V., Ozsoy, A. Z., Genschel, J., Modrich, P. & Kowalczykowski, S. C. Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair. *Proc Natl Acad Sci USA* **105**, 16906–16911, <https://doi.org/10.1073/pnas.0809380105> (2008).
28. Chen, J. *et al.* CRISPR/Cas9-mediated efficient genome editing via blastospore-based transformation in entomopathogenic fungus *Beauveria bassiana*. *Sci Rep* **8**, 45763, <https://doi.org/10.1038/srep45763> (2017).
29. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat Biotechnol* **33**, 543–548, <https://doi.org/10.1038/nbt.3198> (2015).
30. Maruyama, T. *et al.* Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat Biotechnol* **33**, 538–542, <https://doi.org/10.1038/nbt.3190> (2015).
31. Bian, H. & Reed, E. F. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. *J Immunol* **163**, 1010–1018 (1999).
32. Lee, K. W., Shin, J. Y. & Lee, J. Y. Expression defect of an HLA-A*24 allele associated with DNA methylation in a normal individual. *Tissue Antigens* **61**, 325–329 (2003).
33. Tang, T. F. *et al.* Identification of nine new HLA class I alleles in volunteers from the Singapore stem cell donor registries. *Tissue Antigens* **68**, 518–520, <https://doi.org/10.1111/j.1399-0039.2006.00707.x> (2006).
34. Petersdorf, E. W. *et al.* HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. *Blood* **124**, 3996–4003, <https://doi.org/10.1182/blood-2014-09-599969> (2014).
35. DeWitt, M. A. *et al.* Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. *Sci Transl Med* **8**, 360ra134, <https://doi.org/10.1126/scitranslmed.aaf9336> (2016).
36. Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. *Nat Rev Clin Oncol* **10**, 267–276, <https://doi.org/10.1038/nrclinonc.2013.46> (2013).
37. Liu, X. *et al.* CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. *Cell Res* **27**, 154–157, <https://doi.org/10.1038/cr.2016.142> (2017).
38. Clapham, P. R. & Weiss, R. A. Immunodeficiency viruses. Spoilt for choice of co-receptors. *Nature* **388**, 230–231, <https://doi.org/10.1038/40758> (1997).
39. Samson, M. *et al.* Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* **382**, 722–725, <https://doi.org/10.1038/382722a0> (1996).
40. Mandal, P. K. *et al.* Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. *Cell Stem Cell* **15**, 643–652, <https://doi.org/10.1016/j.stem.2014.10.004> (2014).
41. Allers, K. *et al.* Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. *Blood* **117**, 2791–2799, <https://doi.org/10.1182/blood-2010-09-309591> (2011).
42. Tebas, P. *et al.* Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *N Engl J Med* **370**, 901–910, <https://doi.org/10.1056/NEJMoa1300662> (2014).
43. Yin, Y. *et al.* Application of High-Throughput Next-Generation Sequencing for HLA Typing on Buccal Extracted DNA: Results from over 10,000 Donor Recruitment Samples. *PLoS One* **11**, e0165810, <https://doi.org/10.1371/journal.pone.0165810> (2016).
44. Zhang, Q. *et al.* Understanding the correlation between DSA, complement activation and antibody mediated rejection in heart transplant recipients. *Transplantation*, <https://doi.org/10.1097/TP.0000000000002333> (2018).

Acknowledgements

We acknowledged Gemalene Sunga, Nicole Valenzuela, Fadi Kandarian, Zhaohui Wang, Jar-How Lee, Mikki Ozawa, Danny Yu, Hui Jiang, Arlene Locke, Yiping Jin, and Lindsey Harp for providing technical support. This work was supported by grants from the National Institutes of Health: U01 (grant no. 30685-UCLA), P01 (grant no. 1P01AI120944-01), and U19 (grant no. 1U19AI128913-01).

Author Contributions

Q.Z., E.F.R. and Y.Y. conceived the experiments, Y.Y. conducted the experiments, Y.Y. and Q.Z. analyzed the results, Y.Y. and Q.Z. wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-44336-7>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019